|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-5-17
|
|
pubmed:abstractText |
The Department of Health issued guidelines for the NHS treatment of erectile dysfunction (ED) with phosphodiesterase type 5 inhibitors (PDE 5 inhibitors) in 1999. There has been an increasing trend in the prescribing of PDE 5 inhibitors within Bebington and West Wirral Primary Care Trust (PCT) over the 3-year period from February 2001 to January 2004. The objective of the study was to investigate implementation of Government guidelines on prescribing of PDE 5 inhibitors for ED and the cost of prescribing outside these guidelines.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0269-4727
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
297-304
|
|
pubmed:dateRevised |
2008-5-28
|
|
pubmed:meshHeading |
pubmed-meshheading:15896249-3',5'-Cyclic-GMP Phosphodiesterases,
pubmed-meshheading:15896249-Cost-Benefit Analysis,
pubmed-meshheading:15896249-Cyclic Nucleotide Phosphodiesterases, Type 5,
pubmed-meshheading:15896249-Drug Costs,
pubmed-meshheading:15896249-Drug Utilization Review,
pubmed-meshheading:15896249-Erectile Dysfunction,
pubmed-meshheading:15896249-Guideline Adherence,
pubmed-meshheading:15896249-Humans,
pubmed-meshheading:15896249-Male,
pubmed-meshheading:15896249-Phosphodiesterase Inhibitors,
pubmed-meshheading:15896249-Phosphoric Diester Hydrolases,
pubmed-meshheading:15896249-Physician's Practice Patterns,
pubmed-meshheading:15896249-Practice Guidelines as Topic
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
A study of the management of erectile dysfunction in general practice.
|
|
pubmed:affiliation |
School of Pharmacy & Chemistry, Liverpool John Moores University, Liverpool, UK.
|
|
pubmed:publicationType |
Journal Article
|
